降压药减量对住院和死亡的影响:OPTiMISE随机对照试验长期随访
约半数干预组存活者维持了减药,未发现住院或死亡增加。
要点
- 80岁以上、收缩压<150 mmHg且用≥2种降压药者,减一种药未增加全因住院或死亡风险。
核心结论
- 对80岁及以上、血压控制且服用两种以上降压药的老年人,减停一种降压药未观察到全因住院或死亡风险增加。
- 约半数干预组存活参与者在长期随访中维持了减药,提示减药干预可能安全。
研究设计与样本
- OPTiMISE随机对照试验的长期随访,纳入英格兰中部和南部69家全科诊所的569名参与者。
- 参与者年龄≥80岁、收缩压<150 mmHg且服用≥2种降压药,1:1随机分配至减停一种降压药组或常规护理组。
- 通过初级和二级电子健康记录随访至少3年,主要结局为全因住院或死亡时间,采用Cox回归意向性分析。
主要发现
- 随访时干预组存活213人中109人(51%)维持减药。
临床怎么用
- 对80岁及以上、收缩压<150 mmHg且服用≥2种降压药的老年人,可考虑减停一种降压药并长期监测。
- 减药决策需结合个体情况,长期随访未显示全因住院或死亡风险增加。
局限性
- 参与者和全科医生知晓分组,可能影响行为。
- 随访依赖电子健康记录,可能存在记录不完整。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Deprescribing of antihypertensive medications is recommended for some older patients with low blood pressure and frailty. The OPTiMISE trial showed that this deprescribing can be achieved with no differences in blood pressure control at 3 months compared with usual care. We aimed to examine effects of deprescribing on longer-term hospitalisation and mortality. METHODS: This randomised controlled trial enrolled participants from 69 general practices across central and southern England. Participants aged 80 years or older, with systolic blood pressure less than 150 mm Hg and who were receiving two or more antihypertensive medications, were randomly assigned (1:1) to antihypertensive medication reduction (removal of one antihypertensive) or usual care. General practitioners and participants were aware of the treatment allocation following randomisation but individuals responsible for analysing the data were masked to the treatment allocation throughout the study. Participants were followed up via their primary and secondary care electronic health records at least 3 years after randomisation. The primary outcome was time to all-cause hospitalisation or mortality. Intention-to-treat analyses were done using Cox regression modelling. A per-protocol analysis of the primary outcome was also done, excluding participants from the intervention group who did not reduce treatment or who had medication reinstated during the initial trial 12-week follow-up period. This study is registered with the European Union Drug Regulating Authorities Clinical Trials Database (EudraCT2016-004236-38) and the ISRCTN Registry (ISRCTN97503221). FINDINGS: Between March 20, 2017, and Sept 30, 2018, a total of 569 participants were randomly assigned. Of these, 564 (99%; intervention=280; control=284) were followed up for a median of 4·0 years (IQR 3·7-4·3). Participants had a mean age of 84·8 years (SD 3·4) at baseline and 273 (48%) were women. Medication reduction was sustained in 109 participants at follow-up (51% of the 213 participants alive in the intervention group). Participants in the intervention group had a larger reduction in antihypertensives than the control group (adjusted mean difference -0·35 drugs [95% CI -0·52 to -0·18]). Overall, 202 (72%) participants in the intervention group and 218 (77%) participants in the control group experienced hospitalisation or mortality during follow-up (adjusted hazard ratio [aHR] 0·93 [95% CI 0·76 to 1·12]). There was some evidence that the proportion of participants experiencing the primary outcome in the per-protocol population was lower in the intervention group (aHR 0·80 [0·64 to 1·00]). INTERPRETATION: Half of participants sustained medication reduction with no evidence of an increase in all-cause hospitalisation or mortality. These findings suggest that an antihypertensive deprescribing intervention might be safe for people aged 80 years or older with controlled blood pressure taking two or more antihypertensives. FUNDING: British Heart Foundation and National Institute for Health and Care Research.
引用
- Sheppard JP, Temple E, Wang A, et al. Effect of antihypertensive deprescribing on hospitalisation and mortality: long-term follow-up of the OPTiMISE randomised controlled trial. Lancet Healthy Longev. 2024. PMID: 39094592. doi:10.1016/S2666-7568(24)00131-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。